Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Factors associated with positive thrombus findings at ultrasonography in COVID-19 ward patients who underwent imaging for suspected deep vein thrombosis under prophylactic anticoagulation

Abdulerkerim Özhan, MD,a and Murat Bastopcu, MD,b Kütahya and Bitlis, Turkey

ABSTRACT

Objective: The incidence of deep vein thrombosis (DVT) is increased in patients with coronavirus disease 2019 (COVID-19) and its presence is associated with worse outcomes. Ultrasound examination of patients with COVID-19 with a suspected DVT is challenging owing to concerns with disease transmission; the timely initiation of therapeutic anticoagulation is essential. This study aimed to identify patient factors associated with positive thrombus findings at ultrasound examination in patients with COVID-19 who underwent imaging for suspected DVT.

Methods: Patients who did not require intensive care unit treatment and who underwent ultrasound imaging for suspected DVT between March and December 2020 were included retrospectively. Patient demographics, comorbidities, modified Well’s score, and d-dimer results on the day of ultrasound examination were recorded. Parameters for a higher likelihood of a positive DVT result were determined by comparing patients with confirmed DVT on ultrasound examination and patients with negative ultrasound findings. To determine a cut-off for d-dimer levels, a receiver operating characteristic curve was constructed. The sensitivity and specificity of the determined high-risk factors in the prediction of positive ultrasound results were calculated.

Results: A positive history for DVT (25% vs 4%; \( P < .001 \)), thrombophilia (9% vs 2%; \( P = .048 \)), immobilization (53% vs 23%; \( P = .001 \)), and a Well’s score \( \geq 2 \) (50% vs 21%; \( P = .001 \)) were more frequent in patients with DVT. The mean d-dimer levels were higher in patients with DVT (3871 ± 1805 vs 2075 ± 1543; \( P < .001 \)). The presence of either thrombophilia or a d-dimer level of \( >2020 \) had a sensitivity of 93% and a specificity of 64%. The presence of either thrombophilia, a d-dimer level of \( >2020 \), or a Well’s score of \( \geq 2 \) had a sensitivity of 100% and a specificity of 51%.

Conclusions: Patients with COVID-19 with a d-dimer of \( >2020 \), a positive history for thrombophilia, and a Well’s score of \( \geq 2 \) should undergo a timely ultrasound examination. The high risk of DVT should be remembered for all hospitalized patients with COVID-19. (J Vasc Surg Venous Lymphat Disord 2022;10:811-7.)

Keywords: COVID-19; Deep vein thrombosis; Doppler ultrasound

The novel coronavirus disease 2019 (COVID-19) can cause severe respiratory disease and is associated with significant morbidity in cases that require hospitalization. It is well-established that the incidence of venous thromboembolism (VTE) is increased in patients with COVID-19. Early in the pandemic, prophylactic anticoagulation was recommended for all patients with COVID-19 without increased risk of bleeding. Despite prophylactic treatment, deep vein thrombosis (DVT) is encountered frequently and impacts the course of the disease.\(^1\) In severe disease, VTE is markedly increased, with an incidence exceeding 20% in intensive care unit (ICU) patients.\(^2,3\) Reports from patients from general wards have also shown frequent VTE. Among non-ICU patients, incidences between 12% and 26% were reported in screening studies, with most cases being asymptomatic.\(^4-6\) Prophylactic anticoagulation does not completely preclude VTE events in ward patients.\(^7\) With this high incidence among COVID-19 cases, clinical suspicion of VTE should be kept in mind for all hospitalized patients.

The initial workup for suspected DVT includes a detailed anamnesis, careful evaluation of the extremities, and d-dimer testing.\(^8\) The value of classical scoring methods may be less helpful in the setting of COVID-19 wards. Normal d-dimer levels help to exclude DVT; however, its levels are increased in the early stages of the
COVID-19 infection. Higher d-dimer levels indicate a more severe infection and are also prognostic for patients with COVID-19. Because of the hyperinflammatory environment resulting in high d-dimer levels, higher cutoffs may guide the physician for the diagnosis of VTE.

Owing to concerns with transmission and equipment cleanliness, clinicians may hesitate to rapidly perform an ultrasound examination when DVT is suspected. The proper use of ultrasound devices and personnel can ensure the optimal treatment of patients with COVID-19 while minimizing the risk for medical personnel. There is no current guideline on the timing of ultrasound imaging for patients with COVID-19 with suspected DVT and institutional protocols may vary. With an awareness of the substantial risk in patients with COVID-19, clinicians are vigilant for the signs of DVT. Imaging studies are ordered for all suspected cases because there are no globally accepted guidelines on the timing of ultrasound for DVT in COVID-19. This factor may cause increased transmission of the virus, and the prudent use of imaging facilities may be necessary in centers that treat patients with and without COVID-19.

The aim of this study was to identify the parameters associated with positive findings of venous thrombus in COVID-19 ward patients who underwent ultrasound imaging for suspected DVT.

**METHODS**

This study was performed in a single referral center that treated patients with COVID-19. Patients who did not require ICU treatment and who underwent ultrasound imaging for suspected DVT between March and December 2020 were included retrospectively. Approval was obtained from the institutional ethics board for this study and the study was conducted in accordance with the Declaration of Helsinki. Individual patient consent was waived owing to the retrospective nature of the study.

The national guidelines set forth by the Ministry of Health for the diagnosis and treatment of COVID-19 were followed. The diagnosis of COVID-19 was made with symptoms of fever, cough, dyspnea, musculoskeletal pain, or other flu-like symptoms together with a positive reverse-transcriptase polymerase chain reaction test or radiological findings of COVID-19 pneumonia. The national guideline categorizes patients according to their severity. Mild cases with symptoms of fever, cough, throat ache, and musculoskeletal pain, but without dyspnea (respiratory rate of <24/min, SpO2 of >93%) or radiological findings of COVID-19 pneumonia are recommended for home treatment with isolation and close follow-up. A moderate COVID-19 infection is diagnosed with dyspnea (respiratory rate of <30/min, SpO2 of >90%) and radiological findings of COVID-19 pneumonia. Cases with moderate infection are hospitalized per the national guideline. The diagnosis of severe pneumonia is made when tachypnea (respiratory rate of >30) or hypoxia (SpO2 of ≤90%) existed together with radiological findings of COVID-19 pneumonia and warrants ICU admission. Patients with accompanying hypotension, acute kidney injury, acute liver dysfunction, confusion, immunosuppression, or other acute organ dysfunctions are also admitted to the ICU.

The standard treatment for COVID-19 infection included favipiravir and intravenous methylprednisolone for hospitalized patients. Our institutional protocol was to administer DVT prophylaxis to all hospitalized patients with COVID-19, including leg elevation and a single dose of low-molecular-weight heparin, unless active bleeding was demonstrated. Sequential compression, TED hose, or other compression stockings were not used for prophylaxis. Patients with improving symptoms and elevated d-dimer levels at the time of discharge were continued on prophylactic anticoagulation with single dose daily enoxaparin for 1 month if no contraindications were present. Patients with VTE were continued their anticoagulation for 6 months. At admission, d-dimer was measured for all patients. In case of suspected VTE, d-dimer measurements were repeated before ordering an ultrasound study. An ultrasound study was ordered when patients had at least one of the following: calf or whole leg swelling compared with the contralateral leg, new-onset tenderness, or pain in the lower extremity. Patient demographics, comorbidities, the modified Well’s score, and d-dimer results on the day of ultrasound examination were recorded.

Parameters for a higher likelihood of a positive DVT result were determined by comparing patients with confirmed DVT at ultrasound examination and patients with negative ultrasound findings. A history of a previous DVT was declared by the patient or confirmed with hospital records, when available. Thrombophilia was defined as a known coagulation abnormality (antithrombin III, protein C or S deficiency, factor V Leiden mutation, or other known diseases with abnormal clotting) declared...
by the patient or present in the hospital records. Immobilization was defined as being bedridden for >3 days owing to current COVID-19 disease or previous trauma, neurological disorder, surgery, or other diseases. Recent surgery was defined as any surgery with regional or general anesthesia within the previous 3 months.

**Statistical analysis.** Statistical analysis was carried out using IBM SPSS Statistics 22 software (Armonk, NY). Nominal variables are presented as numbers and percentages while continuous variables are presented as mean and standard deviation. For group comparison, the $\chi^2$ test or Fisher’s exact test was applied for nominal variables, the Student $t$ test for continuous variables with normal distribution, and the Mann-Whitney $U$ test for continuous variables without a normal distribution. Different multivariate models were created with factors significantly associated with positive ultrasound findings at univariate analysis. A receiver operating characteristic curve was constructed for the diagnostic ability of $\alpha$-dimer in predicting DVT. Youden’s index was used to determine the cut-off for $\alpha$-dimer in discriminating positive findings at ultrasound examination. Significance was set at a $P$ value of <.05.

**RESULTS**
During the study period, 945 patients were treated outside of the ICU setting; 168 (18%) were suspected of DVT and were included in the study. The mean age of the study patients was 63 ± 18 years and 71 (42%) were female. Of these patients who were ordered an ultrasound examination, 32 (19%) were diagnosed with DVT, with an overall incidence of 3% among general ward patients.

| Table I. Comparison of patients with and without deep vein thrombosis (DVT) on ultrasound examination |
|---------------------------------------------------------------|
| **No DVT (n = 132)** | **DVT (n = 32)** | **$P$ value** |
| Age                | 62 ± 16          | 63 ± 22          | .253          |
| Female gender      | 60 (44%)         | 11 (34%)         | .315          |
| DM                 | 73 (54%)         | 9 (28%)          | .009          |
| Hypertension       | 87 (64%)         | 17 (53%)         | .256          |
| Chronic pulmonary disease | 58 (43%) | 10 (31%) | .237          |
| Coronary artery disease | 36 (27%) | 4 (13%) | .095          |
| Chronic heart failure | 24 (18%) | 4 (13%) | .482          |
| Chronic renal disease | 30 (22%) | 2 (6%) | .040          |
| History of DVT     | 5 (4%)           | 8 (25%)          | <.001         |
| Venous insufficiency | 10 (7%)      | 2 (6%)           | .827          |
| Thrombophilia      | 2 (2%)           | 3 (9%)           | .048          |
| Immobilization     | 32 (24%)         | 17 (53%)         | .001          |
| Active malignancy  | 21 (15%)         | 8 (25%)          | .198          |
| Recent surgery     | 24 (18%)         | 4 (13%)          | .482          |
| Pregnancy          | 6 (4%)           | 0 (0%)           | .596          |
| Well’s score ≥ 2   | 28 (21%)         | 16 (50%)         | .001          |
| $\alpha$-Dimer     | 2075 ± 1543      | 3871 ± 1805      | <.001         |

DM, Diabetes mellitus. Boldface entries indicate statistical significance.

| Table II. Multivariate analysis of patient factors with prior deep vein thrombosis (DVT) and immobilization included in the model |
|---------------------------------------------------------------------------------------------------------------------------------|
| **$P$ value** | **OR (95% CI)** |
| DM             | .073            | 0.36 (0.12-1.10) |
| Chronic renal disease | .056      | 0.19 (0.03-1.04) |
| Prior DVT      | .081            | 5.82 (0.80-42.09) |
| Thrombophilia  | .007            | 30.78 (2.58-366.65) |
| Immobilization | .071            | 2.72 (0.92-8.06) |
| $\alpha$-Dimer (each 10-unit increase) | <.001 | 1.01 (1.01-1.01) |

CI, Confidence interval. DM, diabetes mellitus. OR, odds ratio. Boldface entries indicate statistical significance.
Patients with DVT were compared against patients without DVT for demographic properties, clinical findings, and \( \text{d-dimer} \) results (Table I). Patients with DVT less frequently had diabetes mellitus (DM) (28% vs 54%; \( P = .009 \)) or chronic renal disease (6% vs 2%; \( P = .040 \)). A positive history for DVT (25% vs 4%; \( P < .001 \)), thrombophilia (9% vs 2%; \( P = .048 \)), immobilization (53% vs 24%; \( P = .001 \)), and a Well’s score of \( \geq 2 \) (50% vs 21%; \( P = .001 \)) were more frequent in patients with DVT. The mean \( \text{d-dimer} \) levels were higher in patients with DVT (3871 ± 1805 vs 2075 ± 1543; \( P < .001 \)).

A positive history for DVT, thrombophilia, immobilization, a Well’s score of \( \geq 2 \), and elevated \( \text{d-dimer} \) were carried onto multivariate analysis. Because immobilization is a criterion in the Well’s scoring system, two multivariate models were constructed separately with immobilization and Well’s score of \( \geq 2 \). In the first model, multifactorial analysis revealed thrombophilia and high \( \text{d-dimer} \) to be independently associated with positive DVT at ultrasound examination. The odds ratio was 31 for thrombophilia, and 1 for each 10-unit increase in \( \text{d-dimer} \) (Table II). In the second model, thrombophilia, a high Well’s score, and a high \( \text{d-dimer} \) were associated with DVT. DM was negatively associated with DVT. The odds ratio was 28 for thrombophilia, 1 for each 10-unit increase in \( \text{d-dimer} \), and 4 for a Well’s score of \( \geq 2 \) (Table III).

To determine a cut-off for the \( \text{d-dimer} \) levels, a receiver operating characteristic curve was constructed. Using the Youden’s index, a \( \text{d-dimer} \) of 2020 had a sensitivity of 89% and 66% specificity with an area under curve of 0.789 (Fig). The diagnostic ability of high-risk factors in selecting patients for an early ultrasound examination was investigated. The presence of either thrombophilia or a \( \text{d-dimer} \) of \( > 2020 \) had a sensitivity of 93% and a specificity of 64% (Table IV). The presence of either thrombophilia, a \( \text{d-dimer} \) of \( > 2020 \), or a Well’s score of \( \geq 2 \) had a sensitivity of 100% and a specificity of 51% (Table V).

**DISCUSSION**

In patients with a \( \text{d-dimer} \) of \( > 2020 \), thrombophilia, or a Well’s score of \( \geq 2 \), there is a high likelihood of positive results with Doppler when DVT is suspected. The selection of patients for a timely ultrasound examination using these factors may ensure an accurate diagnosis and minimize of disease transmission.

Ultrasound imaging has additional challenges in patients with COVID-19 whose transfer to the imaging units may cause additional transmission and additional risks to the hypoxic patient. Point-of-care ultrasound examination may be necessary, with additional risks for the physician. The patient-to-patient and patient-to-clinician transmission risk may defer a timely ultrasound examination. Our findings do not preclude an imaging study for the definitive diagnosis of DVT in any patients with COVID-19, but can serve as a guide to which patients should be assessed urgently with imaging studies. Although all patients with suspected DVT will have an ultrasound examination ordered, our results may be used to plan institutional protocols in prioritizing ultrasound studies. Patients who are less likely to be positive may be assessed, allowing time for precautions against disease transmission.

Prospective studies with established protocols for DVT imaging are warranted to assess the benefits of patient

**Table III. Multivariate analysis of patient factors with Well’s score included in the model**

| Factor                        | \( P \) value | OR (95% CI)     |
|-------------------------------|--------------|----------------|
| DM                            | .029         | 0.28 (0.09-0.88) |
| Chronic renal disease         | .073         | 0.21 (0.04-1.16) |
| Thrombophilia                 | .008         | 28.41 (2.36-342.62) |
| Well’s Score \( \geq 2 \)     | .014         | 4.01 (1.33-12.14) |
| \( \text{d-dimer} \) (each 10-unit increase) | <.001 | 1.01 (1.01-1.01) |

CI: Confidence interval; DM, diabetes mellitus; OR, odds ratio. Boldface entries indicate statistical significance.
selection and the risk of forgoing imaging in low risk patients. A single-center study evaluated the effectiveness of an algorithm that includes a d-dimer of >4000, swelling, and/or pain in the extremity, with three other parameters for pulmonary embolism (persistent unexplained fever, new-onset hypoxia, late dead space fraction). Their algorithm resulted in a 72% decreased in the number of ultrasound examinations ordered, with therapeutic anticoagulation started on patients whose ultrasound examinations were deferred. In their cohort, a serum d-dimer level of >4000 ng/mL had a sensitivity and specificity of 80% and 70% for DVT, respectively.

COVID-19 is characterized by an inflammatory activation that activates the coagulation cascades in the patient. Being an acute phase reactant, d-dimer levels are elevated both by the acquired thrombotic state and the proinflammatory environment. The elevation in d-dimer is associated with severity of COVID-19 disease, mortality, and VTE. For patients not requiring ICU-level care, higher d-dimer levels were demonstrated in patients with DVT. In parallel, more patients with DVT required transfer to the ICU. Our clinical protocol per our national guideline is to start all hospitalized patients without contraindications on prophylactic anticoagulation. The prothrombotic pathways in COVID-19 disease are being evidenced and there is a remarkable risk of VTE in these patients compared with other viral infections. These patients can severely deteriorate owing to a sudden VTE event. Therefore, the risks of additional anticoagulation are outweighed by the benefits of avoiding limb and pulmonary complications. The detection and due treatment of DVT is important to decrease mortality and complications. In these patients, if ultrasound examination is performed an ultrasound result. In previous reports that included ICU patients, Wells’s score was not a predictor of DVT, possibly owing to the prevalent high Wells scores on many ICU patients regardless of DVT symptoms. The d-dimer level is used in DVT diagnosis, but higher cut-offs are more relevant in COVID-19-associated DVT. The d-dimer levels have been used to guide thromboprophylaxis in COVID-19. In one study that screened all non-ICU patients with COVID-19 with a d-dimer of >1000 ng/mL using Doppler ultrasound examination, a d-dimer of >1570 was associated with the best discriminate capacity. In another study, a d-dimer of >3000 had a positive predictive value of 67%. In other studies that included both ICU and non-ICU patients, cut-offs at 2000 mg/dL and 6494 mg/dL had the best discrimina-

dy.26 It is not, however, part of the routine workup and may not be possible to measure outside of clinical studies, so its effectiveness at the bedside setting may be limited.

In their study on all ICU and non-ICU patients screened with ultrasound examination, Zhang et al. reached the recommendation to perform an ultrasound examination on patients with a CURB-65 score of ≥3, a Padua prediction score of ≥4, and a d-dimer of >1000 ng/mL. The combination of these three findings had a sensitivity of 89% and a specificity of 61% for DVT in hospitalized patients. The Padua prediction score was not collected for our patients, but includes known thrombophilic conditions as a criterion, and several other criteria overlap with the Wells’s score. The CURB-65 score may signify the severity of immune response with the increased severity of pneumonia, which may be more relevant in cohorts that include ICU patients.

Patients with DVT in our study had less DM and chronic renal disease than what has previously been reported.

### Table IV. Diagnostic ability of either thrombophilia or high d-dimer

|          | No DVT | DVT | P value |
|----------|--------|-----|---------|
| Low risk | 81 (64) | 2 (7) | <0.001  |
| High risk| 45 (36) | 25 (93) |          |

Boldface entries indicate statistical significance. Values are number (%).

### Table V. Diagnostic ability of either thrombophilia, high d-dimer, and a Wells’s score of ≥2

|          | No DVT | DVT | P value |
|----------|--------|-----|---------|
| Low risk | 64 (51) | 0 (0) | <0.001  |
| High risk| 62 (49) | 27 (100) |          |

DVT, Deep vein thrombosis. Boldface entries indicate statistical significance. Values are number (%).
Comorbidities of advancing age, hypertension, DM, chronic kidney disease, and malignancy increase the risk of DVT during COVID-19 treatment. This finding is likely due to our exclusion of ICU patients. Patients with these comorbidities are more prone to require treatment in the ICU. In the study by Cho et al., patients with DM less frequently had DVT, but both our and their study was single-center in design and selection bias cannot be excluded.

Our study is limited by its retrospective, single-center design and its inherent limitations. Another limitation is that the level of DVT in our patients was not recorded. Other inflammatory markers such as C-reactive protein or IL-6 were not available for our patients. All patients received anticoagulation, which may make comparisons with other cohorts where the selective use of anticoagulation is implemented difficult. All patients are questioned for known thrombophilia, but patients were not tested for the levels of coagulation parameters and some patients may be unaware of their condition. Our study was not designed to screen for all DVTs in COVID-19 ward patients and some patients may have had silent asymptomatic venous thrombi that became clinically evident after discharge from the hospital. Our study included patients with moderate infection treated in the ward setting and cannot be applied directly to other patients populations, such as those with severe infection treated in the ICU. Because of these limitations and the different comorbidities that may be present in patients hospitalized in different institutions, our results need to be externally validated by studies in other centers.

CONCLUSIONS
All patients hospitalized with COVID-19 carry a substantial DVT risk. patients with COVID-19 with a d-dimer of >2020, a positive history for thrombophilia, and a Well's score of ≥2 should undergo a timely ultrasound examination. The high risk of DVT should be remembered for the levels of coagulation parameters and some patients may be unaware of their condition. Our study was not designed to screen for all DVTs in COVID-19 ward patients and some patients may have had silent asymptomatic venous thrombi that became clinically evident after discharge from the hospital. Our study included patients with moderate infection treated in the ward setting and cannot be applied directly to other patients populations, such as those with severe infection treated in the ICU. Because of these limitations and the different comorbidities that may be present in patients hospitalized in different institutions, our results need to be externally validated by studies in other centers.

AUTHOR CONTRIBUTIONS
Conception and design: AO, MB
Analysis and interpretation: AO, MB
Data collection: AO
Writing the article: AO, MB
Critical revision of the article: AO, MB
Final approval of the article: AO, MB
Statistical analysis: MB
Obtained funding: Not applicable
Overall responsibility: AO

REFERENCES
1. Middeldorp S, Coppens M, van Haaps TF, Poppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020;18:1995-2002.
2. Suh YJ, Hong H, Ohana M, Bompad F, Revel M-P, Valle C, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology 2021;298:E70-80.
3. Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020;46:765-71.
4. Santoliquido A, Porfidia A, Nesici A, De Matteis G, Marone C, Porceddu E, et al. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J Thromb Haemost 2020;18:2358-63.
5. Ierardi AM, Gaibazzi N, Tuttolomondo D, Fusco S, La Mura V, Peyvandi F, et al. Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables. Radiol Med 2021;126:722-8.
6. Trimaiali A, Curtiad A, Marchandot B, Matsushita K, Sato C, Leonard-Lorant I, et al. Venous thromboembolism in non-critically ill patients with COVID-19 infection. Thromb Res 2020;193:166-9.
7. Jimenez-Cuixi X, Huici-Sánchez M, Rímer-Villegas A, Izierdono-Miranda A, Sancho-Cerro A, Vila-Coll R. Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients. J Vasc Surg Venous Lymphat Disord 2021;9:592-6.
8. Kakkos SK, Mohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. Editor's choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg 2021;61:9-82.
9. Elijian J, Elzouki A-N, D-Dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review. Vasc Health Risk Manag 2020;16:455-62.
10. The National Scientific Advisory Board of the Ministry of Health. Covid-19 (SARS-CoV-2) infection treatment of adult patients (in Turkish). Ankara, Turkey; 2021. 1-22. p. Available at: https://covid19.saglik.gov.tr/Eklenti/A2576/Covid19Thromboseriskinhasayetonimivetdevam1-20220222pdf.pdf. Accessed March 4, 2022.
11. Dua A, Thondapu V, Rosovsky R, Hunt D, Latz C, Waller HD, et al. Deep vein thrombosis protocol optimization to minimize healthcare worker exposure in coronavirus disease-2019. J Vasc Surg Venous Lymphat Disord 2021;9:299-306.
12. Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli R, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020;18:1747-51.
13. Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020;120:1642-53.
14. Naymagon L, Zubizarreta N, Feld J, van Gerwen M, Alsen M, Thiba S, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thromb Res 2020;196:99-105.
15. Artifoni M, Damic G, Gauert C, Ciquepl P, Bouteille D, Raffi F, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis 2020;50:211-6.
16. Cai C, Guo Y, You Y, Hu K, Cai F, Xie M, et al. Deep vein thrombosis in COVID-19 patients: a cohort analysis. Clin Appl Thromb 2020;26:107602962098266.
17. Dobesh PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacother J Hum Pharmacol Drug Ther 2020;40:1130-51.
18. Aryal MR, Cosain R, Donato A, Pathak R, Bhatt VR, Katel A, et al. Venous thromboembolism in COVID-19: towards an ideal approach to thromboprophylaxis, screening, and treatment. Curr Cardiol Rep 2020;22:52.
19. Chopard R, Albertsen IE, Piazza G. Diagnosis and treatment of lower extremity venous thromboembolism. JAMA 2020;324:1765.
20. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349:1227-35.
21. Sebuhyan M, Miralles R, Crici B, Frere C, Bonnin P, Bergeron-Lafaurie A, et al. How to screen and diagnose deep vein thrombosis (DVT) in patients hospitalized for or suspected of COVID-19 infection, outside the intensive care units. J Méd Vasc 2020;45:334-43.
22. Cho ES, McClelland PH, Cheng O, Kim Y, Hu J, Zenilman ME, et al. Utility of d-dimer for diagnosis of deep vein thrombosis in
coronavirus disease-19 infection. J Vasc Surg Venous Lymphat Disord 2021;9:47-53.

23. Stawiarski K, Loutoo A, Velardi L, Zarich S. D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19. Thromb Res 2021;201:151-3.

24. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macias M, Toledo-Samaniego N, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 2020;192:23-6.

25. Pieralli F, Pomero F, Giampieri M, Marcucci R, Prisco D, Luise F, et al. Incidence of deep vein thrombosis through an ultrasound surveillance protocol in patients with COVID-19 pneumonia in non-ICU setting: a multicenter prospective study. PLoS One 2021;16:e0251966.

26. Ierardi AM, Coppola A, Fusco S, Stellato E, Aliberti S, Andrisani MC, et al. Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound? J Ultrasound 2021;24:165-73.

27. Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation 2020;142:114-28.

Submitted Sep 3, 2021; accepted Feb 14, 2022.